Diagnos Inc (ADK) - Net Assets
Based on the latest financial reports, Diagnos Inc (ADK) has net assets worth CA$-1.54 Million CAD (≈ $-1.11 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CA$1.17 Million ≈ $847.95K USD) and total liabilities (CA$2.71 Million ≈ $1.96 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check ADK financial resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CA$-1.54 Million |
| % of Total Assets | -131.15% |
| Annual Growth Rate | N/A |
| 5-Year Change | -79.41% |
| 10-Year Change | N/A |
| Growth Volatility | 145.42 |
Diagnos Inc - Net Assets Trend (2002–2025)
This chart illustrates how Diagnos Inc's net assets have evolved over time, based on quarterly financial data. Also explore ADK total assets for the complete picture of this company's asset base.
Annual Net Assets for Diagnos Inc (2002–2025)
The table below shows the annual net assets of Diagnos Inc from 2002 to 2025. For live valuation and market cap data, see Diagnos Inc (ADK) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | CA$233.11K ≈ $168.63K |
+107.64% |
| 2024-03-31 | CA$-3.05 Million ≈ $-2.21 Million |
-56.65% |
| 2023-03-31 | CA$-1.95 Million ≈ $-1.41 Million |
-1616.33% |
| 2022-03-31 | CA$-113.51K ≈ $-82.11K |
-110.03% |
| 2021-03-31 | CA$1.13 Million ≈ $818.98K |
-37.77% |
| 2020-03-31 | CA$1.82 Million ≈ $1.32 Million |
+135.79% |
| 2019-03-31 | CA$-5.08 Million ≈ $-3.68 Million |
-39.76% |
| 2018-03-31 | CA$-3.64 Million ≈ $-2.63 Million |
+34.77% |
| 2017-03-31 | CA$-5.58 Million ≈ $-4.03 Million |
-77.05% |
| 2016-03-31 | CA$-3.15 Million ≈ $-2.28 Million |
-1300.47% |
| 2015-03-31 | CA$-224.85K ≈ $-162.65K |
-164.81% |
| 2014-03-31 | CA$346.95K ≈ $250.98K |
-80.13% |
| 2013-03-31 | CA$1.75 Million ≈ $1.26 Million |
-25.50% |
| 2012-03-31 | CA$2.34 Million ≈ $1.70 Million |
+98.23% |
| 2011-03-31 | CA$1.18 Million ≈ $855.17K |
-40.35% |
| 2010-03-31 | CA$1.98 Million ≈ $1.43 Million |
-17.77% |
| 2009-03-31 | CA$2.41 Million ≈ $1.74 Million |
-42.70% |
| 2008-03-31 | CA$4.21 Million ≈ $3.04 Million |
+195.86% |
| 2007-03-31 | CA$1.42 Million ≈ $1.03 Million |
+79.12% |
| 2006-03-31 | CA$793.68K ≈ $574.14K |
+391.11% |
| 2005-03-31 | CA$161.61K ≈ $116.91K |
+225.52% |
| 2004-03-31 | CA$-128.75K ≈ $-93.14K |
+51.35% |
| 2003-03-31 | CA$-264.64K ≈ $-191.44K |
+18.76% |
| 2002-03-31 | CA$-325.75K ≈ $-235.64K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Diagnos Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 4983173500.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | CA$55.17 Million | 23665.44% |
| Total Equity | CA$233.11K | 100.00% |
Diagnos Inc Competitors by Market Cap
The table below lists competitors of Diagnos Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Akari Therapeutics PLC
NASDAQ:AKTX
|
$16.96 Million |
|
Otto Energy Ltd
AU:OEL
|
$16.96 Million |
|
Kadestone Capital Corp
V:KDSX
|
$16.97 Million |
|
Fondia Oyj
HE:FONDIA
|
$16.98 Million |
|
Intersport Polska S.A.
WAR:IPO
|
$16.95 Million |
|
Lancashire Holdings Ltd
LSE:LRE
|
$16.93 Million |
|
OXE Marine AB
ST:OXE
|
$16.93 Million |
|
PeterLabs Holdings Bhd
KLSE:0171
|
$16.93 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Diagnos Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -3,051,848 to 233,110, a change of 3,284,958.
- Net loss of 4,286,449 reduced equity.
- New share issuances of 7,282,954 increased equity.
- Other comprehensive income decreased equity by 9,894,688.
- Other factors increased equity by 10,183,141.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CA$-4.29 Million | -1838.81% |
| Share Issuances | CA$7.28 Million | +3124.26% |
| Other Comprehensive Income | CA$-9.89 Million | -4244.64% |
| Other Changes | CA$10.18 Million | +4368.38% |
| Total Change | CA$- | % |
Book Value vs Market Value Analysis
This analysis compares Diagnos Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 100.50x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2002-03-31 | CA$-0.11 | CA$0.23 | x |
| 2003-03-31 | CA$-0.25 | CA$0.23 | x |
| 2004-03-31 | CA$-0.09 | CA$0.23 | x |
| 2005-03-31 | CA$0.06 | CA$0.23 | x |
| 2006-03-31 | CA$0.25 | CA$0.23 | x |
| 2007-03-31 | CA$0.39 | CA$0.23 | x |
| 2008-03-31 | CA$1.03 | CA$0.23 | x |
| 2009-03-31 | CA$0.53 | CA$0.23 | x |
| 2010-03-31 | CA$0.41 | CA$0.23 | x |
| 2011-03-31 | CA$0.23 | CA$0.23 | x |
| 2012-03-31 | CA$0.38 | CA$0.23 | x |
| 2013-03-31 | CA$0.27 | CA$0.23 | x |
| 2014-03-31 | CA$0.04 | CA$0.23 | x |
| 2015-03-31 | CA$-0.02 | CA$0.23 | x |
| 2016-03-31 | CA$-0.30 | CA$0.23 | x |
| 2017-03-31 | CA$-0.45 | CA$0.23 | x |
| 2018-03-31 | CA$-0.22 | CA$0.23 | x |
| 2019-03-31 | CA$-0.12 | CA$0.23 | x |
| 2020-03-31 | CA$0.03 | CA$0.23 | x |
| 2021-03-31 | CA$0.02 | CA$0.23 | x |
| 2022-03-31 | CA$0.00 | CA$0.23 | x |
| 2023-03-31 | CA$-0.03 | CA$0.23 | x |
| 2024-03-31 | CA$-0.04 | CA$0.23 | x |
| 2025-03-31 | CA$0.00 | CA$0.23 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Diagnos Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -1838.81%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -4129.65%
- • Asset Turnover: 0.03x
- • Equity Multiplier: 15.60x
- Recent ROE (-1838.81%) is below the historical average (-182.07%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2002 | 0.00% | -45465.96% | 0.02x | 0.00x | CA$-3.15 Million |
| 2003 | 0.00% | -338.90% | 0.94x | 0.00x | CA$-768.45K |
| 2004 | 0.00% | -33.54% | 0.54x | 0.00x | CA$-117.18K |
| 2005 | -1080.43% | -1562.55% | 0.30x | 2.33x | CA$-1.76 Million |
| 2006 | -73.31% | -82.05% | 0.74x | 1.21x | CA$-661.23K |
| 2007 | -43.41% | -79.56% | 0.48x | 1.13x | CA$-759.29K |
| 2008 | -9.46% | -21.37% | 0.38x | 1.16x | CA$-818.68K |
| 2009 | -86.30% | -110.28% | 0.71x | 1.10x | CA$-2.32 Million |
| 2010 | -96.42% | -533.64% | 0.16x | 1.15x | CA$-2.11 Million |
| 2011 | -90.87% | -99.98% | 0.71x | 1.28x | CA$-1.19 Million |
| 2012 | -93.58% | -165.16% | 0.50x | 1.13x | CA$-2.43 Million |
| 2013 | -117.06% | -135.44% | 0.68x | 1.27x | CA$-2.22 Million |
| 2014 | -472.92% | -60.66% | 1.71x | 4.55x | CA$-1.68 Million |
| 2015 | 0.00% | -501.19% | 0.48x | 0.00x | CA$-2.81 Million |
| 2016 | 0.00% | -325.27% | 0.77x | 0.00x | CA$-2.88 Million |
| 2017 | 0.00% | -226.80% | 1.83x | 0.00x | CA$-4.86 Million |
| 2018 | 0.00% | -179.63% | 1.06x | 0.00x | CA$-2.53 Million |
| 2019 | 0.00% | -1175.93% | 0.27x | 0.00x | CA$-3.33 Million |
| 2020 | -185.96% | -1020.42% | 0.14x | 1.34x | CA$-3.56 Million |
| 2021 | -181.19% | -768.07% | 0.14x | 1.72x | CA$-2.16 Million |
| 2022 | 0.00% | -594.35% | 0.28x | 0.00x | CA$-2.60 Million |
| 2023 | 0.00% | -510.72% | 0.59x | 0.00x | CA$-2.29 Million |
| 2024 | 0.00% | -1833.93% | 0.26x | 0.00x | CA$-2.82 Million |
| 2025 | -1838.81% | -4129.65% | 0.03x | 15.60x | CA$-4.31 Million |
Industry Comparison
This section compares Diagnos Inc's net assets metrics with peer companies in the Health Information Services industry.
Industry Context
- Industry: Health Information Services
- Average net assets among peers: $1,118,230
- Average return on equity (ROE) among peers: -70.69%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Diagnos Inc (ADK) | CA$-1.54 Million | 0.00% | N/A | $16.95 Million |
| Comprehensive Healthcare Systems Inc (CHS) | $-6.43 Million | 0.00% | 0.00x | $8.96 Million |
| Carespan Health Inc (CSPN) | $-2.29 Million | 0.00% | 0.00x | $688.89K |
| CardioComm Solutions Inc. (EKG) | $-670.32K | 0.00% | 0.00x | $1.43 Million |
| Kovo Healthtech Corp (KOVO) | $-299.00K | 0.00% | 0.00x | $1.77 Million |
| Kneat.com Inc (KSI) | $11.18 Million | -56.63% | 0.31x | $309.65 Million |
| Newtopia Inc (NEWU) | $4.20 Million | -184.10% | 0.88x | $626.69K |
| NexgenRX Inc. (NXG) | $1.96 Million | -31.90% | 3.93x | $19.03 Million |
| Principal Technologies Inc (PTEC) | $452.37K | -298.34% | 0.68x | $19.20 Million |
| Reliq Health Technologies Inc (RHT) | $1.95 Million | -65.24% | 0.03x | $30.60 Million |
About Diagnos Inc
DIAGNOS Inc. provides software-based services for healthcare sector in Canada, the United States, Mexico, Chile, and internationally. It offers healthcare services through Computer Assisted Retina Analysis, a web-based software tool that assists healthcare professionals for the detection of diabetic retinopathy, as well as allows eye care specialist to visualize normal retinal landmarks and patho… Read more